جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

12 مُخرَج نتائج البحث عن «PI3K/AKT/mTOR pathway»

مراجعةمفتوح (مستودع)202534استشهاد· Semantic Scholar

A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy

Food Science & Nutrition · مجلد 13 (7) · e70608-e70608

The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.

lycopeneanticancer activitymolecular mechanismsantioxidants
مراجعةمفتوح (مستودع)202519استشهاد· Semantic Scholar

Exploring Punicalagin Potential Against Cancers: A Comprehensive Review

Food Science & Nutrition · مجلد 13 (3) · e70072-e70072

Punicalagin, being a bioactive polyphenol, has gained significant interest owing to its potential anticancer effects. Researchers are studying punicalagin to determine its ability to inhibit cancer cell proliferation. This paper focuses on highlighting the therapeutic potential of punicalagin against tumors and cancers. Punicalagin inhibits tumor growth within the body through various cellular pathway interactions. This compound effectively eliminates tumor cells from the liver, stomach, prostate, and lungs. Different animal model studies have demonstrated the potential of punicalagin in blocking the MAPK/ERK and PI3K/AKT/mTOR signaling pathways, fighting against cancer. Through the inhibition of cell division, punicalagin may be capable of eradicating breast cancer cells. Punicalagin strongly inhibits the activities of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and uPA. Punicalagin effectively inhibits the androgen receptor (AR), a protein essential for the development and metastasis of prostate cancer. Lung cancer cells can be eliminated by initiating the caspase cascade and inhibiting protein synthesis, which is facilitated by punicalagin. In numerous animal models, punicalagin significantly reduces metastasis. Cyclokinase B1 and cyclin-dependent kinase 2 promote colon cancer; when colon cancer cells reach the G2/M phase, punicalagin induces apoptosis by inhibiting the action of these proteins. Punicalagin inhibits tumor development and cancer propagation by inhibiting blood vessel proliferation. There is still a need for further clinical trials and studies to fully reveal punicalagin's potential as well as its safety; despite the fact that it may decrease the threat of increasing tumors and provide an alternative treatment for many cancers.

punicalaginpolyphenolsanticancer activityERK signaling
مراجعةمفتوح (مستودع)202517استشهاد· Semantic Scholar

Eugenol: An Insight Into the Anticancer Perspective and Pharmacological Aspects

Food Science & Nutrition · مجلد 13 (8) · e70727-e70727

The aura of the 21st century has been transformed due to a revolutionized health care system and modern industrial applications. However, human health and well-being are still a global challenge, affected by various metabolic and pathological morbidities, causing millions of mortalities. Cancer is one of the leading causes of fatalities globally, occurring due to pathogens, dietary factors, environmental toxins, occupational chemical exposure, and radiation. These factors lead to oxidative stress (OS), inflammation, DNA damage, epigenetic and genetic mutations, cell proliferation, tumorigenesis, and other chronic metabolic disorders such as diabetes mellitus, cardiovascular disorders, gastrointestinal problems, and hepato-renal syndrome. Among various types of cancers, lung cancer is leading them all, followed by breast and colorectal cancer (CRC). The oncogenesis includes activation of pro-inflammatory markers (IL-6, IL-1β, TNF-α), resulting in overexpression of oncogenes, downregulation of tumor suppressor genes (TSGs) like p53, pRb, APC, PTEN, suppression of antioxidant enzymes (GSH, CAT, SOD), and activation of signaling pathways (PI3K/Akt/mTOR/NF-κB, Ras/MAPK). However, plant-based herbal medicine is a valuable, affordable, and available management approach to reduce the risks of oncogenesis and other ailments. The bioactive compounds of these herbs make them an effective way to reduce inflammation, cancer, and the risk of other health problems. Eugenol (Eug), a volatile phenolic bioactive compound with a formula of C10H12O2, has been reported to have anticancer, antidiabetic, cardio- and pulmonary protective roles. Moreover, it can improve gut health and prevent neurodegenerative disorders. According to WHO, the safe dose of eugenol is 2.5 mg/kg for consumption. The current review focuses on the anticancer potential and other pharmacological aspects of eugenol through possible mechanisms.

eugenolanticancer activityoxidative stressinflammation
مراجعةوصول مفتوح20255استشهاد· Semantic Scholar

miRNA regulation of the Akt/mTOR pathway in oral squamous cell carcinoma: a focused review

Discover Oncology · مجلد 16 (1) · 1355-1355

Oral squamous cell carcinoma (OSCC) contributes significantly to global cancer mortality, characterized by a progression from hyperplasia to invasive cancer through a series of genetic and epigenetic alterations. Central to this progression is the Akt/mTOR signaling pathway, which regulates cell proliferation and survival. This review examines the role of microRNAs (miRNAs) in modulating the Akt/mTOR pathway and their implications for OSCC. The Akt/mTOR pathway, activated by receptor tyrosine kinases and involving the PI3K/AKT/mTOR complexes, is crucial for tumor cell growth and metabolism. Dysregulation of this pathway is frequently observed in OSCC, leading to increased proliferation, survival, and metastasis. miRNAs, such as miR-21, miR-99, and miR-145, play significant roles in regulating this pathway by influencing key components like Akt and mTOR. These miRNAs can act as oncogenes or tumor suppressors, affecting cancer progression and response to therapy. The review highlights the potential of targeting miRNAs for OSCC treatment, including strategies to restore normal miRNA levels or inhibit aberrant miRNAs. Such targeted therapies offer promise for improving treatment outcomes and overcoming drug resistance in OSCC.

oral squamous cell carcinomamicroRNAAkt/mTOR signalingPI3K/AKT/mTOR pathway
مقالوصول مفتوح202469استشهاد· Semantic Scholar

RETRACTED: Exploring the molecular mechanisms of MSC-derived exosomes in Alzheimer's disease: Autophagy, insulin and the PI3K/Akt/mTOR signaling pathway

Biomedicine & Pharmacotherapy · مجلد 176 · 116836-116836

Alzheimer's disease (AD) is a devastating neurological condition characterized by cognitive decline, motor coordination impairment, and amyloid plaque accumulation. The underlying molecular mechanisms involve oxidative stress, inflammation, and neuronal degeneration. This study aimed to investigate the therapeutic effects of mesenchymal stem cell-derived exosomes (MSC-exos) on AD and explore the molecular pathways involved, including the PI3K/Akt/mTOR axis, autophagy, and neuroinflammation. To assess the potential of MSC-exos for the treatment of AD, rats were treated with AlCl 3 (17 mg/kg/once/day) for 8 weeks, followed by the administration of an autophagy activator (rapamycin), or MSC-exos with or without an autophagy inhibitor (3-methyladenin; 3-MA+ chloroquine) for 4 weeks. Memory impairment was tested, and brain tissues were collected for gene expression analyses, western blotting, histological studies, immunohistochemistry, and transmission electron microscopy. Remarkably, the administration of MSC-exos improved memory performance in AD rats and reduced the accumulation of amyloid-beta (Aβ) plaques and tau phosphorylation. Furthermore, MSC-exos promoted neurogenesis, enhanced synaptic function, and mitigated astrogliosis in AD brain tissues. These beneficial effects were associated with the modulation of autophagy and the PI3K/Akt/mTOR signalling pathway, as well as the inhibition of neuroinflammation. Additionally, MSC-exos were found to regulate specific microRNAs, including miRNA-21, miRNA-155, miRNA-17–5p, and miRNA-126–3p, further supporting their therapeutic potential. Histopathological and bioinformatic analyses confirmed these findings. This study provides compelling evidence that MSC-exos hold promise as a potential therapeutic approach for AD. By modulating the PI3K/Akt/mTOR axis, autophagy, and neuroinflammation, MSC-exos have the potential to improve memory, reduce Aβ accumulation, enhance neurogenesis, and mitigate astrogliosis. These findings shed light on the therapeutic potential of MSC-exos and highlight their role in combating AD.

Alzheimer's diseasemesenchymal stem cell-derived exosomesPI3K/AKT/mTOR pathwayautophagy
مقالوصول مفتوح202350استشهاد· Semantic Scholar

Anticancer and apoptosis inducing potential of quercetin against a wide range of human malignancies

International Journal of Food Properties · مجلد 26 (1) · 2590-2626

Quercetin, a flavonoid, is a dietary component that has attracted the attention of dietitians and medicinal chemists due to its anticancer potential. It is an antioxidant that has a significant role in reducing different human cancers such as breast, pancreatic, prostate, colon, blood, and oral. Being as an additional anti-cancer agent, it can stop cancer cell invasion and metastasis, induce apoptosis and autophagy, decrease cancer cell growth and proliferation. Multiple mechanisms, including suppression of pathways involved in cell survival, angiogenesis, and inflammation, are thought to be responsible for these anticancer effects. Quercetin has anti-inflammatory properties in both in vitro and in vivo tests, which is important as chronic inflammation is a major contributor to cancer. Preventing the synthesis of cytokines and chemokines that encourage inflammation can support to lessen inflammation and stop the spread of cancer. In cancer cells, quercetin can cause programmed cell death, which can stop the cells from rapidly multiplying and replicating. It provides protection against degradation of DNA induced by radiation and other carcinogens. The PI3K/Akt/mTOR pathway, the NF-κB system, and the Wnt/β-catenin pathway is few of the signaling pathways that quercetin modulates. It can activate the process of autophagy, which breaks the growth and range of cancer by having cells terminate and recover damaged or unwanted cellular mechanisms. The best treatment plans for various cancer kinds will need to be determined through additional research, which will also help confirm its safety and effectiveness in humans.

quercetinflavonoidsanticancer activityapoptosis
مقالوصول مفتوح202335استشهاد· Semantic Scholar

Chrysin a promising anticancer agent: recent perspectives

International Journal of Food Properties · مجلد 26 (1) · 2294-2337

Honey, propolis, and passionflower contain a flavone known as chrysin. Researchers are studying chrysin to prove its potential to stop cancer cells growth. Chrysin cancer therapeutic potential is of great interest and numerous studies have been done to illustrate this potential. It is associated protein pathways effectively suppress tumor growth within the body. It is shown to have the ability to kill breast, prostate, lung, liver, and stomach cancerous cells. It can block Phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling in different animals against various cancers. Chrysin has the potential to kill breast cancer cells in a laboratory setting by inhibiting their cell division. Chrysin strongly suppresses Matrix metalloproteinase-9 (MMP-9), Urokinase plasminogen activator (uPA) and Vascular endothelial growth factor (VEGF), i.e. factors that can cause cancer. Chrysin has the ability to suppress the androgen receptor (AR), a protein necessary for prostate cancer development and metastasis. It starts the caspase cascade and blocks protein synthesis to kill lung cancer cells. Unnecessary apoptosis can be prevented by stopping certain protein pathways. Chrysin significantly decreased lung cancer metastasis in various animal-modeled studies. Chrysin induces apoptosis and stops colon cancer cells in the G2/M cell cycle phase. Chrysin suppresses colon cancer-promoting cyclin B1 and cyclin-dependent kinase 2. Chrysin suppressed cyclin B1 and CDK2 production in order to stop cancerous growth. Chrysin prevents tumor growth and cancer spread by blocking blood vessel expansion. Chrysin’s solubility, accessibility and bioavailability may limit its medical use. Chrysin targets numerous cancer-related communication pathways present in cells. Chrysin may reduce the chances of the onset of cancer, it can also serve as an alternative treatment as a whole to prevent and treat various cancers, but more clinical trials and research studies are needed to fully unlock its potential.

chrysinflavonesanticancer agentshoney
مقالمفتوح (مستودع)202225استشهاد· Semantic Scholar

PI3K/Akt/mTOR Pathways Inhibitors with Potential Prospects in Non-Small-Cell Lung Cancer

Journal of Environmental Pathology Toxicology and Oncology · مجلد 41 (4) · 85-102

Lung cancer is the leading cause of cancer-related mortality across the globe. The most prevalent pathological form of lung cancer is non-small-cell lung cancer (NSCLC). Elevated stimulation of the PI3K/Akt/mTOR pathway causes a slew of cancer-related symptoms, making it a promising target for new anticancer drugs. The PI3K/Akt/mTOR path is involved extensively in carcinogenesis and disease advancement in NSCLC. Several new inhibitors targeting this pathway have been discovered in preclinical investigations and clinical trials. The etiology and epidemiology of NSCLC and biology of the PI3K/Akt/mTOR cascade and its role in NSCLC pathogenesis have all been discussed in this article. In this article, we've reviewed PI3K/Akt/mTOR cascade inhibitors that have been proven in vitro and in preclinical trials to be effective in NSCLC. Drugs targeting the PI3K/Akt/mTOR path in the treatment of NSCLC were also addressed. A better knowledge of the underlying molecular biology, including epigenetic changes, is also critical to detecting relevant biomarkers and guiding combination methods. Additionally, improved clinical trial designs will increase the capacity to test novel drugs and combinations for accounting for genomic variation and eventually improve patient outcomes.

PI3K/AKT/mTOR pathwaynon-small cell lung cancerpathway inhibitorsPI3K inhibitors
مقالوصول مفتوح202214استشهاد· Semantic Scholar

Pioglitazone Synthetic Analogue Ameliorates Streptozotocin-Induced Diabetes Mellitus through Modulation of ACE 2/Angiotensin 1–7 via PI3K/AKT/mTOR Signaling Pathway

Pharmaceuticals · مجلد 15 (3) · 341-341

The renin angiotensin aldosterone system has a localized key regulatory action, especially in liver and body circulation. Furthermore, it accomplishes a significant role in the downregulation of the PI3K/AKT/mTOR signaling pathway that is involved in type II diabetes mellitus pathogenesis. The current study aimed to evaluate the effect of a synthetic pioglitazone analogue (benzenesulfonamide derivative) compared to the standard pioglitazone hypoglycemic drug on enhancing liver insulin sensitivity via ACE 2/Ang (1-7)/PI3K/AKT/mTOR in experimental STZ-induced diabetes. After the model was established, rats were distributed into the normal control group, diabetic group, pioglitazone group (20 mg/kg), and a benzenesulfonamide derivative group (20 mg/kg), with the last 2 groups receiving oral treatment for 14 consecutive days. Our results suggested enhancing liver insulin sensitivity against the ACE2/Ang (1-7)/PI3K/AKT/mTOR pathway. Moreover, the synthetic compound produced a reduction in blood glucose levels, restored hyperinsulinemia back to normal, and enhanced liver glycogen deposition. In addition, it up regulated the ACE2/Ang (1-7)/PI3K/AKT/mTOR signaling pathway via increasing insulin receptor substrate 1 and 2 sensitivity to insulin, while it increased glucose transporter 2 expression in the rat pancreas. The study findings imply that the hypoglycemic effect of the benzenesulfonamide derivative is due to enhancing liver sensitivity to regulate blood glucose level via the ACE2/Ang (1-7)/PI3K/AKT/mTOR pathway.

streptozotocin-induced diabetestype 2 diabetesACE2angiotensin-(1-7)